Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions

被引:140
作者
Barasch, A [1 ]
Peterson, DE [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Sch Dent Med, Dept Oral Diag, Farmington, CT 06030 USA
关键词
oral cavity; mucositis; cancer therapy; pathogenesis; risk factors;
D O I
10.1016/S1368-8375(02)00033-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A multitude of laboratory and clinical research studies of ulcerative oral mucositis induced by cytotoxic cancer therapies have been reported during the past decade. However, a comprehensive understanding of oral mucositis pathogenesis, together with a clear definition of risk factors for development and severity of the lesion, remain under investigation. The literature presents sometimes divergent data regarding these issues, which in turn restrict efforts to develop a unified approach for management of this morbid condition. The current review summarizes these controversies and highlights the need for strategies for stratification of patients enrolled in clinical trials, in relation to both pathophysiologic and associated risk factors. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:91 / 100
页数:10
相关论文
共 91 条
[1]  
ABDELAAL AS, 1989, LANCET, V1, P97
[2]   Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy [J].
Adamietz, IA ;
Rahn, R ;
Bottcher, HD ;
Schafer, V ;
Reimer, K ;
Fleischer, W .
SUPPORTIVE CARE IN CANCER, 1998, 6 (04) :373-377
[3]  
AHMED T, 1993, BONE MARROW TRANSPL, V12, P131
[4]  
Anderson PM, 1998, CANCER, V83, P1433, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1433::AID-CNCR22>3.0.CO
[5]  
2-4
[6]   EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON CHEMOTHERAPY-INDUCED MYELOSUPPRESSION [J].
ANTMAN, KS ;
GRIFFIN, JD ;
ELIAS, A ;
SOCINSKI, MA ;
RYAN, L ;
CANNISTRA, SA ;
OETTE, D ;
WHITLEY, M ;
FREI, E ;
SCHNIPPER, LE .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (10) :593-598
[7]  
BARASCH A, 1995, CANCER, V76, P2550, DOI 10.1002/1097-0142(19951215)76:12<2550::AID-CNCR2820761222>3.0.CO
[8]  
2-X
[9]  
Barasch A, 1998, MT SINAI J MED, V65, P370
[10]  
Bondi E, 1997, ORAL ONCOL, V33, P322